TP A2: Expression profiling based drug design in epidermolysis bullosa acquisita

Epidermolysis bullosa aquisita is an autoimmune blistering disease, which is characterized by autoantibodies against COL VII. Despite of consequent immunosuppressive treatment, patients show a largely increased mortality. Consequently, new therapeutic strategies are urgently required. 23 natural compounds were investigated and 7 showed modulating effects on neutrophil chemotaxis, 5 showed effects on the ROS release and one additionally on CD62L shedding. We now aim to investigate these effects in an in vivo model in order to confirm beneficial effect of the substances and to find a new treatment strategy in autoimmune blistering diseases.